MetaCap

iBio (IBIO) vs XBiotech (XBIT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

iBio (IBIO) has outperformed XBiotech (XBIT) over the past year, losing 23.8% versus a loss of 24.1%. Over five years, XBIT leads with a -86.5% price change compared with -99.8% for IBIO. iBio is the larger company by market cap ($56.4 million vs $52.7 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IBIO-23.80%XBIT-24.12%
+204%+80%-44%
Nov 21, 20251 yearNov 20, 2026
IBIO-99.76%XBIT-86.35%
+7%-49%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IBIO versus XBIT key metrics
MetricIBIOXBIT
Share price$0.8001$1.73
Market cap$56.37M$52.74M
1-day change-0.11%+2.98%
YTD return-58.54%-27.62%
1-year return-23.80%-24.12%
5-year return-99.76%-86.48%
Forward P/E—13.31
EPS (TTM)$-0.27$-1.43
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$100.00K—
Revenue growth (YoY)-75.00%—
Net income (latest FY)$-33.04M$-45.54M
Operating margin-35141.00%—
Net margin-33044.00%—
52-week high$3.82$2.73
52-week low$0.68$1.61
Distance from 52-week high-79.05%-36.63%
Analyst consensusstrong_buy—
Avg. price target upside+611.16%—
Average volume678.91K64.77K
Shares outstanding70.46M30.49M
Employees2387
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About iBio

IBIO stock →

iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides a panel of optimized CD3 antibodies that can be paired with tumor-targeting antibodies to generate bispecific T-cell engagers; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology, small binding sites on large target proteins Its product pipelines for cardiometabolic disease area include IBIO-601, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody designed to inhibit myostatin and activin A signaling to preserve lean mass; IBIO-600 Myostatin Antibody, monoclonal antibody blocking myostatin that is in phase 1; Amylin Antibody, a pancreatic hormone that promotes satiety and appetite control through activation of the amylin receptor; CCR8, a Treg-targeting immunotherapy; and MUC16 antibodies.

Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees

About XBiotech

XBIT stock →

XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees

IBIO vs XBIT FAQ

Which is bigger, iBio or XBiotech?

iBio (IBIO) is larger, with a market capitalization of $56.37M compared with $52.74M for XBiotech (XBIT).

Which stock has performed better over the past year, IBIO or XBIT?

IBIO returned -23.80% over the past 12 months, compared with -24.12% for XBIT (price return, excluding dividends). Past performance does not predict future results.

Are iBio and XBiotech in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons